

Ongoing HVTN Trials: Enrolling, In Follow-up, Annual Health/AESI Contact(s)

| Protocol | Description | Size | Trial Collaborators | Start Date* | Sites | Stage |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|--------------------------------------------------------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------|
| HVTN 096/EV04 | A phase 1 double blind placebo-controlled clinical trial to evaluate the safety and to compare the priming ability of NYVAC alone versus NYVAC + AIDSVAX B/E, and DNA alone versus DNA + AIDSVAX B/E when followed by NYVAC + AIDSVAX B/E boosts in healthy, HIV-1 uninfected adult participants | 96 | HVTN BMGF IPPOX EuroVacc GSID USMHRP DAIDS | Aug 2012 | Lausanne | Annual health/AESI contact(s) |
| HVTN 106 | A phase 1 randomized, double-blind, placebo controlled clinical trial to evaluate the safety and immunogenicity of an HIV-1 vaccine regimen of DNA prime with 3 different HIV-1 envelope inserts (Nat-B env, CON-S env, and Mosaic env) with MVA-CMDR boost in healthy, HIV-1-uninfected adults | 105 | HVTN CHAVI-ID DAIDS EuroVacc LANL USMHRP | Jan 2015 | Atlanta - Hope Clinic; Birmingham; Boston - Brigham; Boston - Fenway; Lausanne; San Francisco; Seattle | Annual health/AESI contact(s) |
| HVTN 107 | A Phase 1/2a partially double-blinded, randomized clinical trial to characterize the safety and immunogenicity of clade C ALVAC-HIV (vCP2438) and Bivalent Subtype C gp120 alone, with MF59® adjuvant, and with alum adjuvant in healthy, HIV-uninfected adult participants | 132 | HVTN DAIDS GSK Sanofi | Jun 2017 | Cape Town - Emavundleni; Durban - eThekweni; Harare - Seke South; Maputo; Soweto - Bara; Tembisa - Clinic 3 | Follow-up (closed to accrual) |
| HVTN 108 | A phase 1/2a clinical trial to evaluate the safety and immunogenicity of HIV clade C DNA, and of MF59®- or AS01B-adjuvanted clade C Env protein, in healthy, HIV-uninfected adult participants | 334 | HVTN DAIDS BMGF GSK IPPOX | Dec 2016 | Birmingham; Boston - Brigham; Boston - Fenway; Cape Town - Emavundleni; Durban - Verulam; Durban - eThekweni; Klerksdorp; Ladysmith; Nashville; New York - NYBC; New York - Physicians & Surgeons; Rochester; Seattle; Soshanguve; Soweto - Bara; Soweto - Kiptown; Tembisa - Clinic 3 | Follow-up (closed to accrual) |
| HVTN 112 | A phase 1 trial to evaluate the safety, tolerability, and immunogenicity of a prime-boost regimen of HIV-1 nef/tat/vif, env pDNA vaccine delivered intramuscularly with electroporation and HIV-1 rVSV envC vaccine in healthy HIV-uninfected adult participants | 15 | HVTN DAIDS Profectus Ichor | Apr 2016 | Cleveland; Philadelphia | Follow-up (closed to accrual) |

*First participant enrolled

Printed 6/4/2019

Ongoing HVTN Trials: Enrolling, In Follow-up, Annual Health/AESI Contact(s)

| Protocol | Description | Size | Trial Collaborators | Start Date* | Sites | Stage |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|------------------------------------------------------------------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------|
| HVTN 114 | A phase I clinical trial to evaluate the immunogenicity of AIDSVAX® B/E bivalent gp120 vaccine and MVA/HIV62B in healthy, HIV-1 uninfected adult participants who previously received MVA/HIV62B in DNA/MVA or MVA/MVA regimens in HVTN 205 | 100 | HVTN DAIDS GeoVax GSID | Feb 2017 | Atlanta - Hope Clinic; Birmingham; Boston - Brigham; Iquitos; Lima - Barranco; Nashville; New York - NYBC; New York - Physicians & Surgeons; Rochester; San Francisco; Seattle | Annual health/AESI contact(s) |
| HVTN 115 | A Phase I clinical trial to evaluate the safety and immunogenicity of EnvSeq-1 and CH505.M5 Envs adjuvanted with GLA-SE, in healthy, HIV-uninfected adult participants | 132 | HVTN DAIDS CHAVI IDRI | Oct 2017 | Birmingham; Boston - Brigham; Nashville; New York - NYBC; New York - Physicians & Surgeons; Philadelphia; Rochester; San Francisco; Seattle | Follow-up (closed to accrual) |
| HVTN 116 | A phase 1 clinical trial to evaluate the safety, pharmacokinetics, and anti-viral activity of VRC HIVMAB060 00 AB (VRC01) and VRC HIVMAB080 00 AB (VRC01LS) in the serum and mucosa of healthy, HIV-uninfected adult participants | 74 | HVTN VRC DAIDS | Mar 2017 | Cape Town - Groote Schuur; Cleveland; Philadelphia; Seattle | Follow-up (closed to accrual) |
| HVTN 119 | A phase 1 clinical trial to evaluate the safety and immunogenicity of pDNA vaccines expressing HIV M Group p24Gag conserved elements and/or p55Gag, administered with IL-12 pDNA by intramuscular electroporation, in healthy, HIV-uninfected adult participants | 56 | HVTN DAIDS Profectus University of Washington Ichor NCI | Nov 2017 | Atlanta - Hope Clinic; Cleveland; San Francisco | Follow-up (closed to accrual) |
| HVTN 120 | A phase 1/2a clinical trial to evaluate the safety and immunogenicity of ALVAC-HIV (vCP2438) and of MF59®- or AS01B-adjuvanted clade C Env protein, in healthy, HIV-uninfected adult participants | 320 | HVTN DAIDS BMGF Sanofi GSK | Feb 2018 | Atlanta - Hope Clinic; Boston - Brigham; Boston - Fenway; Cleveland; Durham; Harare - Seke South; Lusaka - Matero; Mbeya; Nashville; New York - Physicians & Surgeons; Philadelphia; Rochester; San Francisco; Seattle | Follow-up (closed to accrual) |

*First participant enrolled

Printed 6/4/2019

Ongoing HVTN Trials: Enrolling, In Follow-up, Annual Health/AESI Contact(s)

| Protocol | Description | Size | Trial Collaborators | Start Date* | Sites | Stage |
|--------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-------------------------------------------------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------|
| HVTN 121 | A phase 1b open label clinical trial to evaluate HIV-1 neutralization antibody breadth in response to HIV gp120 protein vaccine adjuvanted with aluminum hydroxide in HIV-uninfected adults with quiescent Lupus Erythematosus | 16 | GSID | | Birmingham; Durham | Open to accrual |
| HVTN 122 | A Phase 1 double-blind, randomized clinical trial to evaluate the safety and immunogenicity of MHRP recombinant trimeric gp145 Env in healthy, HIV-1 uninfected adult participants | 45 | HVTN USMHRP DAIDS | Jan 2018 | New York - NYBC; New York - Physicians & Surgeons; Philadelphia | Follow-up (closed to accrual) |
| HVTN 124 | A Phase I clinical trial to evaluate the safety and immunogenicity of Polyvalent env (A, B, C, E)/gag (C) DNA and gp 120 (A,B,C,E) Protein/GLA-SE HIV-1 Vaccines (PDPHV-201401) as either a prime-boost regimen or co-administered in repeated doses, in healthy, HIV-1 uninfected adult participants | 60 | HVTN DAIDS U Mass | Apr 2018 | Atlanta - Hope Clinic; Birmingham; Boston - Fenway; Cleveland; Philadelphia; Rochester | Enrolling |
| HVTN 127/HPTN 087 | A phase 1 clinical trial to evaluate the safety and drug levels of a human monoclonal antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), administered in multiple doses intravenously, subcutaneously, and intramuscularly in different dosing schedules to healthy, HIV-uninfected adults | 100 | HVTN HPTN DAIDS VRC | Feb 2018 | Atlanta - Ponce de Leon; Birmingham; Boston - Brigham; Boston - Fenway; Chapel Hill; Lausanne; New York - Physicians & Surgeons | Follow-up (closed to accrual) |
| HVTN 128 | A Phase I clinical trial to evaluate the safety, pharmacokinetics, and anti-viral activity of VRC-HIVMB075-00-AB (VRC07-523LS) in the serum and mucosa of healthy, HIV-1 uninfected adult participants | 36 | HVTN DAIDS VRC | Jan 2019 | Boston - Brigham; Seattle | Enrolling |
| HVTN 702 | A pivotal phase 2b/3 multi-site, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of ALVAC-HIV (vCP2438) and Bivalent Subtype C gp120/MF59 in preventing HIV-1 infection in adults in South Africa | 5400 | HVTN GSK DAIDS Sanofi Pasteur BMGF MRC | Oct 2016 | Cape Town - Emavundleni; Cape Town - Khayelitsha; Durban - Isipingo; Durban - Verulam; Durban - eThekweni; Klerksdorp; Ladysmith; Medunsa; Mthatha; Rustenburg; Soshanguve; Soweto - Bara; Soweto - Kliptown; Tembisa - Clinic 3 | Enrolling |

*First participant enrolled

Printed 6/4/2019

Ongoing HVTN Trials: Enrolling, In Follow-up, Annual Health/AESI Contact(s)

| Protocol | Description | Size | Trial Collaborators | Start Date* | Sites | Stage |
|--------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|------------------------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|
| HVTN 703/HPTN 081 | A phase 2b study to evaluate the efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection | 1900 | HVTN HPTN DAIDS VRC | May 2016 | Blantyre; Cape Town - Grooten Schuur; Durban - Botha's Hill; Durban - Chatsworth; Durban - eThekwini; Gaborone; Harare - Parirenyatwa; Harare - Seke South; Harare - Spilhaus; Hillbrow; Johannesburg - Ward 21; Kisumu; Klerksdorp; Lilongwe; Mamelodi; Maputo; Mbeya; Rustenburg; Soweto - Bara; Tembisa - Clinic 3; Vulindlela | Follow-up (closed to accrual) |
| HVTN 704/HPTN 085 | A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection among men and transgender persons who have sex with men | 2700 | HVTN HPTN DAIDS VRC | Apr 2016 | Atlanta - Hope Clinic; Atlanta - Ponce de Leon; Birmingham; Boston - Brigham; Boston - Fenway; Chapel Hill; Cleveland; Iquitos; Lausanne; Lima - Barranco; Lima - San Marcos; Lima - San Miguel; Lima - Via Libre; Los Angeles - Vine Street; Nashville; New York - Bronx Prevention; New York - Harlem Prevention; New York - NYBC; New York - Physicians & Surgeons; Newark; Philadelphia; Rio de Janeiro; Rochester; San Francisco; Seattle; Washington - DC | Follow-up (closed to accrual) |

*First participant enrolled

Printed 6/4/2019

Ongoing HVTN Trials: Enrolling, In Follow-up, Annual Health/AESI Contact(s)

| Protocol | Description | Size | Trial Collaborators | Start Date* | Sites | Stage |
|------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------------------------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| HVTN 705/HPX 2008 | A multicenter, randomized, double-blind, placebo-controlled phase 2b efficacy study of a heterologous prime/boost vaccine regimen of Ad26.Mos4.HIV and aluminum phosphate- adjuvanted Clade C gp140 in preventing HIV-1 infection in women in sub-Saharan Africa | 2600 | HVTN Janssen DAIDS BMGF | Nov 2017 | Bloemfontein; Cape Town - Emavundleni; Cape Town - Khayelitsha; Durban - Chatsworth; Durban - Isipingo; Durban - Tongaat; Durban - Verulam; Durban - eThekweni; Elandsdoorn; Harare - Seke South; Harare - St. Mary's; Klerksdorp; Ladysmith; Lilongwe; Lusaka - Matero; Lusaka - ZEHRP; Mamelodi; Maputo; Masiphumelele; Medunsa; Mthatha; Ndola; Rustenburg; Soshanguve; Soweto - Bara; Soweto - Kliptown; Tembisa - Clinic 4 | Enrolling |